MovDisordV3, PascalFrancis, Corpus, bibRecord, 000515

A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease

Identifieur interne : 000515 ( PascalFrancis/Corpus ); précédent : 000514; suivant : 000516

A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease

Auteurs : Holly A. Shill ; Sanja Obradov ; Yakov Katsnelson ; Ray Pizinger

Source :

Movement disorders [ 0885-3185 ] ; 2011.

RBID : Pascal:11-0353391

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Angoisse anxiété, Etat dépressif, Pathologie du système nerveux.

English descriptors

KwdEn :
- Anxiety, Depression, Nervous system diseases, Parkinson disease.

Abstract

We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty-three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unified Parkinson's Disease Rating Scale parts I-III was 29.4 ± 10.0. The primary end point, Unified Parkinson's Disease Rating Scale in week 2 following treatment, reduced by 5.3 ± 9.7 for those in active treatment and 7.7 ± 4.8 for those receiving placebo (not significant). Similarly, no significant differences were seen in the Hamilton Anxiety Scale, Geriatric Depression Scale, and Epworth Sleepiness Scale over the duration of the study. The treatment was well tolerated without device-related adverse events. Despite the negative study, nonpharmacological approaches should continue to be pursued in Parkinson's disease, as they are generally well received by patients.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 26`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease`
A11	`01`	`1`		`@1 SHILL (Holly A.)`
A11	`02`	`1`		`@1 OBRADOV (Sanja)`
A11	`03`	`1`		`@1 KATSNELSON (Yakov)`
A11	`04`	`1`		`@1 PIZINGER (Ray)`
A14	`01`			`@1 Banner Sun Health Research Institute @2 Sun City, Arizona @3 USA @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 Kalaco Scientific, Inc @2 Scottsdale, Arizona @3 USA @Z 3 aut. @Z 4 aut.`
A20				`@1 1477-1480`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000508552620150`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 19 ref.`
A47	`01`	`1`		`@0 11-0353391`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty-three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unified Parkinson's Disease Rating Scale parts I-III was 29.4 ± 10.0. The primary end point, Unified Parkinson's Disease Rating Scale in week 2 following treatment, reduced by 5.3 ± 9.7 for those in active treatment and 7.7 ± 4.8 for those receiving placebo (not significant). Similarly, no significant differences were seen in the Hamilton Anxiety Scale, Geriatric Depression Scale, and Epworth Sleepiness Scale over the duration of the study. The treatment was well tolerated without device-related adverse events. Despite the negative study, nonpharmacological approaches should continue to be pursued in Parkinson's disease, as they are generally well received by patients.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Angoisse anxiété @5 02`
C03	`02`	`X`	`ENG`	`@0 Anxiety @5 02`
C03	`02`	`X`	`SPA`	`@0 Angustia ansiedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Etat dépressif @5 03`
C03	`03`	`X`	`ENG`	`@0 Depression @5 03`
C03	`03`	`X`	`SPA`	`@0 Estado depresivo @5 03`
C03	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 04`
C03	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 04`
C03	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 04`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Affect affectivité @5 42`
C07	`05`	`X`	`ENG`	`@0 Affect affectivity @5 42`
C07	`05`	`X`	`SPA`	`@0 Afecto afectividad @5 42`
C07	`06`	`X`	`FRE`	`@0 Trouble de l'humeur @5 43`
C07	`06`	`X`	`ENG`	`@0 Mood disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Trastorno humor @5 43`
N21				`@1 241`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0353391 INIST
ET :	A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease
AU :	SHILL (Holly A.); OBRADOV (Sanja); KATSNELSON (Yakov); PIZINGER (Ray)
AF :	Banner Sun Health Research Institute/Sun City, Arizona/Etats-Unis (1 aut., 2 aut.); Kalaco Scientific, Inc/Scottsdale, Arizona/Etats-Unis (3 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 8; Pp. 1477-1480; Bibl. 19 ref.
LA :	Anglais
EA :	We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty-three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unified Parkinson's Disease Rating Scale parts I-III was 29.4 ± 10.0. The primary end point, Unified Parkinson's Disease Rating Scale in week 2 following treatment, reduced by 5.3 ± 9.7 for those in active treatment and 7.7 ± 4.8 for those receiving placebo (not significant). Similarly, no significant differences were seen in the Hamilton Anxiety Scale, Geriatric Depression Scale, and Epworth Sleepiness Scale over the duration of the study. The treatment was well tolerated without device-related adverse events. Despite the negative study, nonpharmacological approaches should continue to be pursued in Parkinson's disease, as they are generally well received by patients.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Angoisse anxiété; Etat dépressif; Pathologie du système nerveux
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Affect affectivité; Trouble de l'humeur
ED :	Parkinson disease; Anxiety; Depression; Nervous system diseases
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Affect affectivity; Mood disorder
SD :	Parkinson enfermedad; Angustia ansiedad; Estado depresivo; Sistema nervioso patología
LO :	INIST-20953.354000508552620150
ID :	11-0353391

Links to Exploration step

Pascal:11-0353391

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease</title>
<author><name sortKey="Shill, Holly A" sort="Shill, Holly A" uniqKey="Shill H" first="Holly A." last="Shill">Holly A. Shill</name>
<affiliation><inist:fA14 i1="01"><s1>Banner Sun Health Research Institute</s1>
<s2>Sun City, Arizona</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Obradov, Sanja" sort="Obradov, Sanja" uniqKey="Obradov S" first="Sanja" last="Obradov">Sanja Obradov</name>
<affiliation><inist:fA14 i1="01"><s1>Banner Sun Health Research Institute</s1>
<s2>Sun City, Arizona</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Katsnelson, Yakov" sort="Katsnelson, Yakov" uniqKey="Katsnelson Y" first="Yakov" last="Katsnelson">Yakov Katsnelson</name>
<affiliation><inist:fA14 i1="02"><s1>Kalaco Scientific, Inc</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pizinger, Ray" sort="Pizinger, Ray" uniqKey="Pizinger R" first="Ray" last="Pizinger">Ray Pizinger</name>
<affiliation><inist:fA14 i1="02"><s1>Kalaco Scientific, Inc</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0353391</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0353391 INIST</idno>
<idno type="RBID">Pascal:11-0353391</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000515</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease</title>
<author><name sortKey="Shill, Holly A" sort="Shill, Holly A" uniqKey="Shill H" first="Holly A." last="Shill">Holly A. Shill</name>
<affiliation><inist:fA14 i1="01"><s1>Banner Sun Health Research Institute</s1>
<s2>Sun City, Arizona</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Obradov, Sanja" sort="Obradov, Sanja" uniqKey="Obradov S" first="Sanja" last="Obradov">Sanja Obradov</name>
<affiliation><inist:fA14 i1="01"><s1>Banner Sun Health Research Institute</s1>
<s2>Sun City, Arizona</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Katsnelson, Yakov" sort="Katsnelson, Yakov" uniqKey="Katsnelson Y" first="Yakov" last="Katsnelson">Yakov Katsnelson</name>
<affiliation><inist:fA14 i1="02"><s1>Kalaco Scientific, Inc</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pizinger, Ray" sort="Pizinger, Ray" uniqKey="Pizinger R" first="Ray" last="Pizinger">Ray Pizinger</name>
<affiliation><inist:fA14 i1="02"><s1>Kalaco Scientific, Inc</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term>
<term>Depression</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Angoisse anxiété</term>
<term>Etat dépressif</term>
<term>Pathologie du   système nerveux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty-three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unified Parkinson's Disease Rating Scale parts I-III was 29.4 ± 10.0. The primary end point, Unified Parkinson's Disease Rating Scale in week 2 following treatment, reduced by 5.3 ± 9.7 for those in active treatment and 7.7 ± 4.8 for those receiving placebo (not significant). Similarly, no significant differences were seen in the Hamilton Anxiety Scale, Geriatric Depression Scale, and Epworth Sleepiness Scale over the duration of the study. The treatment was well tolerated without device-related adverse events. Despite the negative study, nonpharmacological approaches should continue to be pursued in Parkinson's disease, as they are generally well received by patients.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SHILL (Holly A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>OBRADOV (Sanja)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KATSNELSON (Yakov)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PIZINGER (Ray)</s1>
</fA11>
<fA14 i1="01"><s1>Banner Sun Health Research Institute</s1>
<s2>Sun City, Arizona</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Kalaco Scientific, Inc</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>1477-1480</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000508552620150</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0353391</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty-three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unified Parkinson's Disease Rating Scale parts I-III was 29.4 ± 10.0. The primary end point, Unified Parkinson's Disease Rating Scale in week 2 following treatment, reduced by 5.3 ± 9.7 for those in active treatment and 7.7 ± 4.8 for those receiving placebo (not significant). Similarly, no significant differences were seen in the Hamilton Anxiety Scale, Geriatric Depression Scale, and Epworth Sleepiness Scale over the duration of the study. The treatment was well tolerated without device-related adverse events. Despite the negative study, nonpharmacological approaches should continue to be pursued in Parkinson's disease, as they are generally well received by patients.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Angoisse anxiété</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Anxiety</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Angustia ansiedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Depression</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Affect affectivité</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Affect affectivity</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Afecto afectividad</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>43</s5>
</fC07>
<fN21><s1>241</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0353391 INIST</NO>
<ET>A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease</ET>
<AU>SHILL (Holly A.); OBRADOV (Sanja); KATSNELSON (Yakov); PIZINGER (Ray)</AU>
<AF>Banner Sun Health Research Institute/Sun City, Arizona/Etats-Unis (1 aut., 2 aut.); Kalaco Scientific, Inc/Scottsdale, Arizona/Etats-Unis (3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 8; Pp. 1477-1480; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<EA>We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty-three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unified Parkinson's Disease Rating Scale parts I-III was 29.4 ± 10.0. The primary end point, Unified Parkinson's Disease Rating Scale in week 2 following treatment, reduced by 5.3 ± 9.7 for those in active treatment and 7.7 ± 4.8 for those receiving placebo (not significant). Similarly, no significant differences were seen in the Hamilton Anxiety Scale, Geriatric Depression Scale, and Epworth Sleepiness Scale over the duration of the study. The treatment was well tolerated without device-related adverse events. Despite the negative study, nonpharmacological approaches should continue to be pursued in Parkinson's disease, as they are generally well received by patients.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Angoisse anxiété; Etat dépressif; Pathologie du   système nerveux</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Affect affectivité; Trouble de l'humeur</FG>
<ED>Parkinson disease; Anxiety; Depression; Nervous system diseases</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Affect affectivity; Mood disorder</EG>
<SD>Parkinson enfermedad; Angustia ansiedad; Estado depresivo; Sistema nervioso patología</SD>
<LO>INIST-20953.354000508552620150</LO>
<ID>11-0353391</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000515 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000515 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0353391
   |texte=   A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease

A Randomized, Double-Blind Trial of Transcranial Electrostimulation in Early Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri